A new real-world study of Oregon’s state-licensed, nonmedical psilocybin program found the program’s outcomes were largely favorable and overall quite safe. Published in JAMA Network Open, the analysis drew on nearly 350 participants who received psilocybin at state-licensed centers. Led by researchers at Oregon Health & Science University, the study reported that many participants described the experience as beneficial and more than half ranked it among the most meaningful events of their lives. Only a small number reported serious adverse reactions. The study adds to a growing evidence base for regulated psychedelic services that differ from typical clinical-development trial settings. It also contrasts the Oregon model—with supervision by facilitators—with earlier skepticism about dosing people outside tightly controlled medical environments. While the work does not substitute for large randomized drug-development trials, it provides an additional safety and real-world experience reference point for regulators and developers tracking the pathway toward potential FDA approvals for therapeutic psychedelins.